Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Minerva Neurosciences Q1 2024 GAAP EPS $(1.13) Beats $(1.20) Estimate; Cash, Cash Equivalents And Restricted Cash Of $34.9M

Author: Benzinga Newsdesk | May 01, 2024 08:16am
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.20) by 5.83 percent. This is a 13.74 percent increase over losses of $(1.31) per share from the same period last year.

Posted In: NERV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist